MannKind Plunges on Securities Offering
Shares of biotech name MannKind (NASDAQ: MNKD) had lost nearly 9 percent on Tuesday after the company filed to sell up to $500 million in mixed securities. Year-to-date, the stock has lost less than 1 percent and over the last 52-weeks, MNKD is down almost 16 percent.
MannKind Corporation is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.